Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Sell
20
VTGN Quote, Financials, Valuation and Earnings
Last price:
$0.67
Seasonality move
:
20.93%
Day range:
$0.66 - $0.71
52-week range:
$0.63 - $5.14
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
23.17x
P/B ratio:
0.39x
Volume:
1.7M
Avg. volume:
4.6M
1-year change:
-78.21%
Market cap:
$26.1M
Revenue:
$486K
EPS (TTM):
-$1.90
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VTGN
Vistagen Therapeutics, Inc.
|
$139.5K | -$0.49 | -40.39% | -5.71% | $0.97 |
|
DARE
Daré Bioscience, Inc.
|
$765K | -$0.43 | 2911.81% | -13.48% | $10.75 |
|
GOVX
GeoVax Labs, Inc.
|
-- | -- | -100% | -- | $9.63 |
|
OMER
Omeros Corp.
|
-- | $0.16 | -- | -0.15% | $38.00 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$59.3M | -- | 11.45% | -- | $13.63 |
|
XOMA
XOMA Royalty Corp.
|
$11.1M | -$0.09 | 27.73% | -80.01% | $64.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VTGN
Vistagen Therapeutics, Inc.
|
$0.66 | $0.97 | $26.1M | -- | $0.00 | 0% | 23.17x |
|
DARE
Daré Bioscience, Inc.
|
$1.98 | $10.75 | $28.3M | 95.38x | $0.00 | 0% | 399.70x |
|
GOVX
GeoVax Labs, Inc.
|
$0.17 | $9.63 | $4.9M | -- | $0.00 | 0% | 0.72x |
|
OMER
Omeros Corp.
|
$12.49 | $38.00 | $885.5M | -- | $0.00 | 0% | -- |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$7.33 | $13.63 | $433.2M | -- | $0.00 | 0% | 2.03x |
|
XOMA
XOMA Royalty Corp.
|
$29.85 | $64.50 | $369.6M | 40.04x | $0.54 | 0% | 10.38x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VTGN
Vistagen Therapeutics, Inc.
|
2.73% | 1.873 | 1.35% | 5.66x |
|
DARE
Daré Bioscience, Inc.
|
74.07% | -0.066 | 27.91% | 1.09x |
|
GOVX
GeoVax Labs, Inc.
|
-- | 1.979 | -- | 2.75x |
|
OMER
Omeros Corp.
|
254.22% | -2.814 | 126.5% | 0.76x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | -0.960 | 3.7% | 2.92x |
|
XOMA
XOMA Royalty Corp.
|
54.99% | 1.607 | 26.95% | 3.38x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VTGN
Vistagen Therapeutics, Inc.
|
$73K | -$20.1M | -74.76% | -76.57% | -7772.48% | -$13.8M |
|
DARE
Daré Bioscience, Inc.
|
-$610.6K | -$3.7M | -459.12% | -- | -159660.87% | -$616.8K |
|
GOVX
GeoVax Labs, Inc.
|
-$16.8K | -$6.4M | -433.69% | -433.69% | -635.8% | -$6.2M |
|
OMER
Omeros Corp.
|
-$240K | -$26.4M | -59.56% | -- | -- | -$18.5M |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
|
XOMA
XOMA Royalty Corp.
|
$8.5M | -$1.3M | 7.44% | 17.31% | -14.22% | -$957K |
Vistagen Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns VTGN or DARE?
Daré Bioscience, Inc. has a net margin of -7525.97% compared to Vistagen Therapeutics, Inc.'s net margin of -154904.35%. Vistagen Therapeutics, Inc.'s return on equity of -76.57% beat Daré Bioscience, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VTGNVistagen Therapeutics, Inc.28.3% -$0.54 $68.2M DAREDaré Bioscience, Inc.-26547.83% -$0.28 $11M -
What do Analysts Say About VTGN or DARE?
Vistagen Therapeutics, Inc. has a consensus price target of $0.97, signalling upside risk potential of 46.44%. On the other hand Daré Bioscience, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 442.93%. Given that Daré Bioscience, Inc. has higher upside potential than Vistagen Therapeutics, Inc., analysts believe Daré Bioscience, Inc. is more attractive than Vistagen Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTGNVistagen Therapeutics, Inc.0 5 0 DAREDaré Bioscience, Inc.3 0 0 -
Is VTGN or DARE More Risky?
Vistagen Therapeutics, Inc. has a beta of 0.307, which suggesting that the stock is 69.277% less volatile than S&P 500. In comparison Daré Bioscience, Inc. has a beta of 0.785, suggesting its less volatile than the S&P 500 by 21.454%.
-
Which is a Better Dividend Stock VTGN or DARE?
Vistagen Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daré Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics, Inc. pays -- of its earnings as a dividend. Daré Bioscience, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTGN or DARE?
Vistagen Therapeutics, Inc. quarterly revenues are $258K, which are larger than Daré Bioscience, Inc. quarterly revenues of $2.3K. Vistagen Therapeutics, Inc.'s net income of -$19.4M is lower than Daré Bioscience, Inc.'s net income of -$3.6M. Notably, Vistagen Therapeutics, Inc.'s price-to-earnings ratio is -- while Daré Bioscience, Inc.'s PE ratio is 95.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics, Inc. is 23.17x versus 399.70x for Daré Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTGNVistagen Therapeutics, Inc.23.17x -- $258K -$19.4M DAREDaré Bioscience, Inc.399.70x 95.38x $2.3K -$3.6M
-
Which has Higher Returns VTGN or GOVX?
GeoVax Labs, Inc. has a net margin of -7525.97% compared to Vistagen Therapeutics, Inc.'s net margin of -630.04%. Vistagen Therapeutics, Inc.'s return on equity of -76.57% beat GeoVax Labs, Inc.'s return on equity of -433.69%.
Company Gross Margin Earnings Per Share Invested Capital VTGNVistagen Therapeutics, Inc.28.3% -$0.54 $68.2M GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M -
What do Analysts Say About VTGN or GOVX?
Vistagen Therapeutics, Inc. has a consensus price target of $0.97, signalling upside risk potential of 46.44%. On the other hand GeoVax Labs, Inc. has an analysts' consensus of $9.63 which suggests that it could grow by 5712.2%. Given that GeoVax Labs, Inc. has higher upside potential than Vistagen Therapeutics, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Vistagen Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTGNVistagen Therapeutics, Inc.0 5 0 GOVXGeoVax Labs, Inc.4 0 0 -
Is VTGN or GOVX More Risky?
Vistagen Therapeutics, Inc. has a beta of 0.307, which suggesting that the stock is 69.277% less volatile than S&P 500. In comparison GeoVax Labs, Inc. has a beta of 3.675, suggesting its more volatile than the S&P 500 by 267.454%.
-
Which is a Better Dividend Stock VTGN or GOVX?
Vistagen Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeoVax Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics, Inc. pays -- of its earnings as a dividend. GeoVax Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTGN or GOVX?
Vistagen Therapeutics, Inc. quarterly revenues are $258K, which are larger than GeoVax Labs, Inc. quarterly revenues of --. Vistagen Therapeutics, Inc.'s net income of -$19.4M is lower than GeoVax Labs, Inc.'s net income of -$6.3M. Notably, Vistagen Therapeutics, Inc.'s price-to-earnings ratio is -- while GeoVax Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics, Inc. is 23.17x versus 0.72x for GeoVax Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTGNVistagen Therapeutics, Inc.23.17x -- $258K -$19.4M GOVXGeoVax Labs, Inc.0.72x -- -- -$6.3M
-
Which has Higher Returns VTGN or OMER?
Omeros Corp. has a net margin of -7525.97% compared to Vistagen Therapeutics, Inc.'s net margin of --. Vistagen Therapeutics, Inc.'s return on equity of -76.57% beat Omeros Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VTGNVistagen Therapeutics, Inc.28.3% -$0.54 $68.2M OMEROmeros Corp.-- -$0.47 $143M -
What do Analysts Say About VTGN or OMER?
Vistagen Therapeutics, Inc. has a consensus price target of $0.97, signalling upside risk potential of 46.44%. On the other hand Omeros Corp. has an analysts' consensus of $38.00 which suggests that it could grow by 204.24%. Given that Omeros Corp. has higher upside potential than Vistagen Therapeutics, Inc., analysts believe Omeros Corp. is more attractive than Vistagen Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTGNVistagen Therapeutics, Inc.0 5 0 OMEROmeros Corp.2 2 0 -
Is VTGN or OMER More Risky?
Vistagen Therapeutics, Inc. has a beta of 0.307, which suggesting that the stock is 69.277% less volatile than S&P 500. In comparison Omeros Corp. has a beta of 2.380, suggesting its more volatile than the S&P 500 by 138.029%.
-
Which is a Better Dividend Stock VTGN or OMER?
Vistagen Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics, Inc. pays -- of its earnings as a dividend. Omeros Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTGN or OMER?
Vistagen Therapeutics, Inc. quarterly revenues are $258K, which are larger than Omeros Corp. quarterly revenues of --. Vistagen Therapeutics, Inc.'s net income of -$19.4M is higher than Omeros Corp.'s net income of -$21.2M. Notably, Vistagen Therapeutics, Inc.'s price-to-earnings ratio is -- while Omeros Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics, Inc. is 23.17x versus -- for Omeros Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTGNVistagen Therapeutics, Inc.23.17x -- $258K -$19.4M OMEROmeros Corp.-- -- -- -$21.2M
-
Which has Higher Returns VTGN or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of -7525.97% compared to Vistagen Therapeutics, Inc.'s net margin of -40.15%. Vistagen Therapeutics, Inc.'s return on equity of -76.57% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.
Company Gross Margin Earnings Per Share Invested Capital VTGNVistagen Therapeutics, Inc.28.3% -$0.54 $68.2M VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M -
What do Analysts Say About VTGN or VNDA?
Vistagen Therapeutics, Inc. has a consensus price target of $0.97, signalling upside risk potential of 46.44%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.63 which suggests that it could grow by 85.88%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Vistagen Therapeutics, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Vistagen Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTGNVistagen Therapeutics, Inc.0 5 0 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is VTGN or VNDA More Risky?
Vistagen Therapeutics, Inc. has a beta of 0.307, which suggesting that the stock is 69.277% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.647%.
-
Which is a Better Dividend Stock VTGN or VNDA?
Vistagen Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTGN or VNDA?
Vistagen Therapeutics, Inc. quarterly revenues are $258K, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Vistagen Therapeutics, Inc.'s net income of -$19.4M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Vistagen Therapeutics, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics, Inc. is 23.17x versus 2.03x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTGNVistagen Therapeutics, Inc.23.17x -- $258K -$19.4M VNDAVanda Pharmaceuticals, Inc.2.03x -- $56.3M -$22.6M
-
Which has Higher Returns VTGN or XOMA?
XOMA Royalty Corp. has a net margin of -7525.97% compared to Vistagen Therapeutics, Inc.'s net margin of 52.48%. Vistagen Therapeutics, Inc.'s return on equity of -76.57% beat XOMA Royalty Corp.'s return on equity of 17.31%.
Company Gross Margin Earnings Per Share Invested Capital VTGNVistagen Therapeutics, Inc.28.3% -$0.54 $68.2M XOMAXOMA Royalty Corp.90.59% $0.70 $239.9M -
What do Analysts Say About VTGN or XOMA?
Vistagen Therapeutics, Inc. has a consensus price target of $0.97, signalling upside risk potential of 46.44%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $64.50 which suggests that it could grow by 116.08%. Given that XOMA Royalty Corp. has higher upside potential than Vistagen Therapeutics, Inc., analysts believe XOMA Royalty Corp. is more attractive than Vistagen Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTGNVistagen Therapeutics, Inc.0 5 0 XOMAXOMA Royalty Corp.4 0 0 -
Is VTGN or XOMA More Risky?
Vistagen Therapeutics, Inc. has a beta of 0.307, which suggesting that the stock is 69.277% less volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.889, suggesting its less volatile than the S&P 500 by 11.101%.
-
Which is a Better Dividend Stock VTGN or XOMA?
Vistagen Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Vistagen Therapeutics, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios VTGN or XOMA?
Vistagen Therapeutics, Inc. quarterly revenues are $258K, which are smaller than XOMA Royalty Corp. quarterly revenues of $9.4M. Vistagen Therapeutics, Inc.'s net income of -$19.4M is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, Vistagen Therapeutics, Inc.'s price-to-earnings ratio is -- while XOMA Royalty Corp.'s PE ratio is 40.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics, Inc. is 23.17x versus 10.38x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTGNVistagen Therapeutics, Inc.23.17x -- $258K -$19.4M XOMAXOMA Royalty Corp.10.38x 40.04x $9.4M $10.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
